(1996). A recombinant protein based on the Trypanosoma cruzi metacyclic trypomastigote 82-kilodalton antigen that induces and effective immune response to acute infection.
(2006). Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.
(2007). Blood donor screening for Chagas disease—United States,
(2005). CD8 +-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.
(2002). Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy.
(2003). Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL15 but not IL-2 induces long-lasting cellular immunity.
(2005). Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help.
(2009). Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus
(1999). Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein.
(1999). Expression of trans-sialidase and 85-kDa glycoprotein genes in Trypanosoma cruzi is differentially regulated at the post-transcriptional level by labile protein factors.
(2002). Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.
(1997). Identification of Trypanosoma cruzi transsialidase family members as targets of protective CD8 + TC1 responses.
(1999). IL-15 prolongs the duration of CD8 + T cellmediated immunity in mice infected with a vaccine strain of Toxoplasma gondii.
(2002). IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.
(2010). Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz
(1998). Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice.
(2009). Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.
(2001). Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999).
(2000). Involvement of CD4 + Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi.
(2006). Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase.
(2005). Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity.
(2004). Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase.
(2010). Regulation of memory T cells by gammac cytokines.
(1999). revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.
(1992). Stage-specific expression and intracellular shedding of the cell surface trans-sialidase of Trypanosoma cruzi.
(2001). The IL15R alpha chain signals through association with Syk in human B cells.
(2007). Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving CD8 + CTL and B cell-mediated cross-priming.
(1993). Trypanosoma cruzi: antibody production and T cell response induced by stage-specific surface glycoproteins purified from metacyclic trypomastigotes.
(2005). Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.